MedPath
HSA Product

PANTOBEX DELAYED RELEASE TABLET 20MG

Product approved by Health Sciences Authority (SG)

Basic Information

PANTOBEX DELAYED RELEASE TABLET 20MG

TABLET, DELAYED RELEASE

Regulatory Information

SIN16591P

September 1, 2022

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XA02BC02

Company Information

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Active Ingredients

Detailed Information

Contraindications

**4.3 Contraindications** Pantobex should generally not be used in cases of known hypersensitivity to one of the other constituents of Pantobex 20 mg, Pantobex 40 mg tablet or of the combination partners. Pantobex 40 mg tablet must not be used in combination treatment for eradication of H.pylori in patients with moderate to severe liver or kidney function disturbances since currently no clinical data are available on the efficacy and safety of Pantoprazole 40 mg in combination treatment of these patients.

Indication Information

**4.1. Therapeutic indications** **_Pantobex Delayed Release Tablet 20_ mg** - Mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing). - Long-term management and prevention of relapse in reflux oesophagitis. - Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti- inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment. **_Pantobex Delayed Release Tablet 40_ mg** - In combination with two appropriate antibiotics (see Dosage) for the eradication of H.pylori in patients with peptic ulcers with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism. - Duodenal ulcer - Gastric ulcer - Moderate and severe reflux oesophagitis

© Copyright 2025. All Rights Reserved by MedPath